

The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

Description	Lot #	Exp Date	NDC	UPC
DOXY SUC PYR HCL DR10MG TEV100	100028023	08/31/2023	00591213201	30591213201
DOXY SUC PYR HCL DR10MG TEV100	100025842	08/31/2023	00591213201	30591213201
S DOXY SUC PYR HCL10MG*MST*100	100028023	08/31/2023	00591213201	30591213201
S DOXY SUC PYR HCL10MG*MST*100	100025842	08/31/2023	00591213201	30591213201

Teva is recalling the above item/lot(s) because assay results are below specification limits for the active ingredient. A decrease in bioavailability and clinical efficacy is the main safety concern that may arise from this quality incident which could potentially cause an exacerbation of nausea and vomiting in pregnant women taking the affected lots. This recall is to the retail level. Affected product started shipping October 19, 2021.